Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Abstract 6225: SERPINB3 promotes the aggressive basal-like/squamous subtype and correlates with poor prognosis in pancreatic ductal adenocarcinoma through metabolic reprogramming

Yuuki Ohara, Wei Tang, Liu Huaitian, Shouhui Yang, Peijun He, Helen Cawley, Paloma Valenzuela, Lin Zhang, Jochen Gaedcke, B. Michael Ghadimi, Matthias M. Gaida, Frank Bergmann, H. Richard Alexander, Nader Hanna, Stefan Ambs, S. Perwez Hussain

Cancer Res (2023) 83 (7_Supplement): 6225.

https://doi.org/10.1158/1538-7445.AM2023-6225

Published: 04 April 2023

View articletitled, Abstract 6225: SERPINB3 promotes the aggressive basal-like/squamous subtype and correlates with poor prognosis in pancreatic ductal adenocarcinoma through metabolic reprogramming

Journal Articles

Abstract 2860: NOSTRIN-induced inhibition of pancreatic cancer progression involves CCBE1 in an eNOS-independent manner

Lin Zhang, Shouhui Yang, Limin Wang, Peijun He, Ohara Yuuki, Paloma Valenzuela, Wei Tang, Jochen Gaedcke, B. Michael Ghadim, Matthias M. Gaida, Frank Bergmann, H. Richard Alexander, Nader Hanna, Brid M Ryan, S. Perwez Hussain

Cancer Res (2021) 81 (13_Supplement): 2860.

https://doi.org/10.1158/1538-7445.AM2021-2860

Published: 01 July 2021

View articletitled, Abstract 2860: NOSTRIN-induced inhibition of pancreatic cancer progression involves CCBE1 in an eNOS-independent manner

Journal Articles

Abstract C61: Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer

Shouhui Yang, Wei Tang, Peijun He, Limin Wang, Jochen Gaedcke, B. Michael Ghadim, Philipp Ströbel, Azadeh Azizian, Matthias M. Gaida, Frank Bergmann, H. Richard Alexander, Nader Hanna, S. Perwez Hussain

Cancer Res (2019) 79 (24_Supplement): C61.

https://doi.org/10.1158/1538-7445.PANCA19-C61

Published: 13 December 2019

View articletitled, Abstract C61: Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer

Journal Articles

Abstract 4789: A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2

Cancer Res (2017) 77 (13_Supplement): 4789.

https://doi.org/10.1158/1538-7445.AM2017-4789

Published: 01 July 2017

View articletitled, Abstract 4789: A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2

Journal Articles

Abstract B34: A Novel MIF-driven Signaling Drives Disease Aggressiveness by Targeting NR3C2 in Pancreatic Cancer

Shouhui Yang, Peijun He, Jian Wang, Aaron Schetter, Wei Tang, Naotake Funamizu, Katsuhiko Yanaga, Tadashi Uwagawa, Abhay R. Satoskar, Jochen Gaedcke, Markus Bernhardt, B. Michael Ghadimi, Matthias M. Gaida, Frank Bergmann, Jens Werner, Thomas Ried, Nader Hanna, H. Richard Alexander, S. Perwez Hussain

Cancer Res (2016) 76 (24_Supplement): B34.

https://doi.org/10.1158/1538-7445.PANCA16-B34

Published: 14 December 2016

View articletitled, Abstract B34: A Novel MIF-driven Signaling Drives Disease Aggressiveness by Targeting NR3C2 in Pancreatic Cancer

Journal Articles

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2

Cancer Res (2016) 76 (13): 3838–3850.

https://doi.org/10.1158/0008-5472.CAN-15-2841

Published: 30 June 2016

View articletitled, A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2

Includes: Supplementary data

Journal Articles

Abstract 922: Macrophage migration inhibitory factor (MIF) and miR-301b interactively enhance disease aggressiveness by targeting NR3C2 (nuclear receptor subfamily group c member 2) in human pancreatic cancer

Shouhui Yang, Peijun He, Jian Wang, Aaron Schetter, Wei Tang, Naotake Funamizu, Jochen Gaedcke, Michael Ghadimi, Matthias Gaida, Thomas Ried, Nader Hannah, H. Richard Alexander, S. Perwez Hussain

Cancer Res (2015) 75 (15_Supplement): 922.

https://doi.org/10.1158/1538-7445.AM2015-922

Published: 01 August 2015

View articletitled, Abstract 922: Macrophage migration inhibitory factor (MIF) and miR-301b interactively enhance disease aggressiveness by targeting NR3C2 (nuclear receptor subfamily group c member 2) in human pancreatic cancer

Journal Articles

Abstract 923: Nitric oxide signaling pathway as a pathogenic driver in pancreatic cancer

Jian Wang, Peijun He, Matthias M. Gaida, Shouhui Yang, Aaron Schetter, Jochen Gaedcke, Michael Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Jonathan M. Weiss, Nadar Hanna, H. Richard Alexander, S. Perwez Hussain

Cancer Res (2015) 75 (15_Supplement): 923.

https://doi.org/10.1158/1538-7445.AM2015-923

Published: 01 August 2015

View articletitled, Abstract 923: Nitric oxide signaling pathway as a pathogenic driver in pancreatic cancer

Journal Articles

Abstract 4363: Macrophage migration inhibitory factor (MIF) and miR-301b interactively enhance disease aggressiveness by targeting NR3C2 in human pancreatic cancer

Shouhui Yang, Peijun He, Jian Wang, Aaron Schetter, Naotake Funamizu, Katsuhiko Yanaga, Jochen Gaedcke, B. Michael Ghadimi, Matthias M. Gaida, Thomas Ried, Nader Hanna, H. Richard Alexander, S. Perwez Hussain

Cancer Res (2014) 74 (19_Supplement): 4363.

https://doi.org/10.1158/1538-7445.AM2014-4363

Published: 01 October 2014

View articletitled, Abstract 4363: Macrophage migration inhibitory factor (MIF) and miR-301b interactively enhance disease aggressiveness by targeting NR3C2 in human pancreatic cancer

Journal Articles

Abstract 926: Nitric oxide enhances tumor progression and disease aggressiveness in pancreatic cancer

Jian Wang, Peijun He, Matthias M. Gaida, Shouhui Yang, Aaron Schetter, Jochen Gaedcke, Michael Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Jonathan M. Weiss, Jim Stauffer, Nader Hanna, H. Richard Alexander, S. Perwez Hussain

Cancer Res (2014) 74 (19_Supplement): 926.

https://doi.org/10.1158/1538-7445.AM2014-926

Published: 01 October 2014

View articletitled, Abstract 926: Nitric oxide enhances tumor progression and disease aggressiveness in pancreatic cancer

Journal Articles

Abstract A103: FOXL1 suppresses tumor growth and invasiveness and predicts clinical outcome in human pancreatic ductal adenocarcinoma (PDAC).

Geng Zhang, S. Perwez Hussain, Peijun He, Jochen Gaedcke, Michael B. Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Nader Hannah, H. Richard Alexander

Cancer Res (2012) 72 (14_Supplement): A103.

https://doi.org/10.1158/1538-7445.PANCA2012-A103

Published: 03 April 2014

View articletitled, Abstract A103: FOXL1 suppresses tumor growth and invasiveness and predicts clinical outcome in human pancreatic ductal adenocarcinoma (PDAC).

Journal Articles

FOXL1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer

Geng Zhang, Peijun He, Jochen Gaedcke, B. Michael Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Nader Hanna, H. Richard Alexander, S. Perwez Hussain

Cancer Res (2013) 73 (17): 5416–5425.

https://doi.org/10.1158/0008-5472.CAN-13-0362

Published: 02 September 2013

View articletitled, FOXL1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer

Includes: Supplementary data

Journal Articles

Comparison of reverse phase protein microarray (RPMA) data analysis methods using receiver operator characteristic curves

Gerhard Mundinger, Kathy Calvo, Joanna Shih, Mary Winters, Satoshi Nishizuka, Emmanuel Petricoin, Lance Liotta, James Pingpank, H. Richard Alexander

Cancer Res (2007) 67 (9_Supplement): 2464.

Published: 01 May 2007

View articletitled, Comparison of reverse phase protein microarray (RPMA) data analysis methods using receiver operator characteristic curves

Journal Articles

Real-time in vivo proteomic cell signaling profiles of human tumor responses to regional perfusion chemotherapy identifies phosphorylation changes in Akt and mTor that correlate with clinical outcome

Katherine R. Calvo, Gerhard S. Mundinger, Clifford Marks, Mary Winters, Virginia Espina, Emanuel F. Petricoin, III, Lance A. Liotta, H. Richard Alexander, James F. Pingpank

Cancer Res (2006) 66 (8_Supplement): 849–850.

Published: 15 April 2006

View articletitled, Real-time in vivo proteomic cell signaling profiles of human tumor responses to regional perfusion chemotherapy identifies phosphorylation changes in Akt and mTor that correlate with clinical outcome

Journal Articles

Identification of distinct gene expression profiles in peritoneal versus liver metastases in patients with advanced colorectal adenocarcinoma

Monika L. Burness, Hui Xu, Jennifer Rosen, H. Richard Alexander, Jr.

Cancer Res (2005) 65 (9_Supplement): 1323–1324.

Published: 01 May 2005

View articletitled, Identification of distinct gene expression profiles in peritoneal versus liver metastases in patients with advanced colorectal adenocarcinoma

Journal Articles

Real time in vivo proteomic molecular signaling profiles of human tumors, pre and post tumor perfusion with chemotherapy

Katherine R. Calvo, Virginia Espina, Stephanie M. Hoatson, Adrianna S. Rodriguez, Dara Aisner, Emanuel F. Petricoin, III, H. Richard Alexander, Jr, Lance A. Liotta, James F. Pingpank, Jr

Cancer Res (2005) 65 (9_Supplement): 619.

Published: 01 May 2005

View articletitled, Real time in vivo proteomic molecular signaling profiles of human tumors, pre and post tumor perfusion with chemotherapy

Journal Articles

Targeting effects of colloidal gold bound tumor necrosis factor (TNF) to tumor neovasculature permeability using in vivo video microscopy (IVVM)

Jeffrey M. Farma, Derrick D. Cox, Perry A. Soriano, Giulio F. Paciotti, Lonnie Myer, Lawrence Tamarkin, H. Richard Alexander

Cancer Res (2005) 65 (9_Supplement): 272.

Published: 01 May 2005

View articletitled, Targeting effects of colloidal gold bound tumor necrosis factor (TNF) to tumor neovasculature permeability using in vivo video microscopy (IVVM)

Journal Articles

Modulation of Tumor-host Interactions, Angiogenesis, and Tumor Growth by Tissue Inhibitor of Metalloproteinase 2 via a Novel Mechanism

Andrew L. Feldman, William G. Stetler-Stevenson, Nick G. Costouros, Vladimir Knezevic, Galina Baibakov, H. Richard Alexander, Jr., Dominique Lorang, Stephen M. Hewitt, Dong-Wan Seo, Marshall S. Miller, Sarah O’Connor, Steven K. Libutti

Cancer Res (2004) 64 (13): 4481–4486.

https://doi.org/10.1158/0008-5472.CAN-03-2929

Published: 01 July 2004

View articletitled, Modulation of Tumor-host Interactions, Angiogenesis, and Tumor Growth by Tissue Inhibitor of Metalloproteinase 2 via a Novel Mechanism

Journal Articles

Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors

Chiara Mazzanti, Martha A. Zeiger, Nick Costourous, Christopher Umbricht, William H Westra, Danelle Smith, Helina Somervell, Generoso Bevilacqua, H. Richard Alexander, Steven K. Libutti

Cancer Res (2004) 64 (8): 2898–2903.

https://doi.org/10.1158/0008-5472.CAN-03-3811

Published: 15 April 2004

View articletitled, Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors

Journal Articles

A novel PDE4 inhibitory agent with endothelial cell specific activity.

Jennifer E. Rosen, Walter Miller, Mei He, Sarah O’Connor, H. Richard Alexander, Faribourz Payvandi, David Stirling, Peter Schafer, Steven K. Libutti

Cancer Res (2004) 64 (7_Supplement): 549.

Published: 01 April 2004

View articletitled, A novel PDE4 inhibitory agent with endothelial cell specific activity.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 6225: SERPINB3 promotes the aggressive basal-like/squamous subtype and correlates with poor prognosis in pancreatic ductal adenocarcinoma through metabolic reprogramming

Abstract 2860: NOSTRIN-induced inhibition of pancreatic cancer progression involves CCBE1 in an eNOS-independent manner

Abstract C61: Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer

Abstract 4789: A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2

Abstract B34: A Novel MIF-driven Signaling Drives Disease Aggressiveness by Targeting NR3C2 in Pancreatic Cancer

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2

Abstract 922: Macrophage migration inhibitory factor (MIF) and miR-301b interactively enhance disease aggressiveness by targeting NR3C2 (nuclear receptor subfamily group c member 2) in human pancreatic cancer

Abstract 923: Nitric oxide signaling pathway as a pathogenic driver in pancreatic cancer

Abstract 4363: Macrophage migration inhibitory factor (MIF) and miR-301b interactively enhance disease aggressiveness by targeting NR3C2 in human pancreatic cancer

Abstract 926: Nitric oxide enhances tumor progression and disease aggressiveness in pancreatic cancer

Abstract A103: FOXL1 suppresses tumor growth and invasiveness and predicts clinical outcome in human pancreatic ductal adenocarcinoma (PDAC).

FOXL1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer

Comparison of reverse phase protein microarray (RPMA) data analysis methods using receiver operator characteristic curves

Real-time in vivo proteomic cell signaling profiles of human tumor responses to regional perfusion chemotherapy identifies phosphorylation changes in Akt and mTor that correlate with clinical outcome

Identification of distinct gene expression profiles in peritoneal versus liver metastases in patients with advanced colorectal adenocarcinoma

Real time in vivo proteomic molecular signaling profiles of human tumors, pre and post tumor perfusion with chemotherapy

Targeting effects of colloidal gold bound tumor necrosis factor (TNF) to tumor neovasculature permeability using in vivo video microscopy (IVVM)

Modulation of Tumor-host Interactions, Angiogenesis, and Tumor Growth by Tissue Inhibitor of Metalloproteinase 2 via a Novel Mechanism

Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors

A novel PDE4 inhibitory agent with endothelial cell specific activity.

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only